Advances in the treatment of acute myeloid leukaemia with FLT3 inhibitors
10.3969/j.issn.1671-8348.2023.23.025
- VernacularTitle:FLT3抑制剂治疗急性髓系白血病的研究进展
- Author:
Shun LINGHU
1
;
Qing XIAO
;
Li WANG
Author Information
1. 重庆医科大学附属第一医院血液内科,重庆 400016
- Keywords:
acute myeloid leukemia;
FMS-like tyrosine kinase-3 inhibitor;
targeted therapy;
review
- From:
Chongqing Medicine
2023;52(23):3658-3664
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukaemia(AML)is a highly heterogeneous haematological malignancy,in which FMS like tyrosine kinase 3(FLT3)gene mutation is one of the common gene mutations in AML.Pa-tients with FLT3 mutations have a high relapse rate and poor prognosis,making FLT3 one of the most prom-ising targets for the treatment of AML.At present,the first and second generation inhibitors have entered clinical research successively,among which Midostaurin,Giletitinib,and Quizartinib have been approved for the treatment of AML patients.The combination of FLT3 inhibitors with standard chemotherapeutic drugs can improve the remission rate of the disease,and also have better efficacy in subsequent maintenance therapy or transplant patients,which can improve the overall prognosis of patients.However,some patients may devel-op drug resistance.Developing new FLT3 inhibitors or combining FLT3 inhibitors with other drugs can reduce the development of drug resistance.This article reviewed the research progress of common FLT3 inhibitors in the treatment of AML,in order to provide reference for clinical practice.
